Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 20;8(3):387.
doi: 10.3390/jcm8030387.

Golimumab for Rheumatoid Arthritis

Eleftherios Pelechas  1 , Paraskevi V Voulgari  2 , Alexandros A Drosos  3
Affiliations
Review

Golimumab for Rheumatoid Arthritis

Eleftherios Pelechas et al. J Clin Med. .

Abstract

Since the advent of infliximab for the treatment of rheumatoid arthritis (RA), new genetically-engineered molecules have appeared. This review aims to present the current data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity are all being investigated, not only through phase III trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-MORE, GO-FURTHER, GO-NICE), but also through studies of real-world data. It seems that GLM in the subcutaneous form is an efficacious molecule with a good safety profile at the standard dosage scheme, but a 100 mg subcutaneous dose is associated with a higher risk of opportunistic infections, lymphoma and demyelination. Furthermore, when compared to other tumor necrosis factor-α molecules, it is non-inferior, and, at some points, such as when it comes to immunogenicity and persistence of the drug, it has a better profile. In summary, GLM is an effective, well-tolerated option for the treatment of RA, for both the clinician and patients who are seeking a convenient dosage scheme.

Keywords: TNFα; efficacy; golimumab; immunogenicity; rheumatoid arthritis; tolerability.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McInnes I.B., Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337. doi: 10.1016/S0140-6736(17)31472-1. - DOI - PubMed
    1. Pelechas E., Voulgari P.V., Drosos A.A. ABP501 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 2018;18:317–322. doi: 10.1080/14712598.2018.1430760. - DOI - PubMed
    1. Pelechas E., Drosos A.A. Etanercept biosimilars SB-4. Expert Opin. Biol. Ther. 2019;19:173–179. doi: 10.1080/14712598.2019.1566456. - DOI - PubMed
    1. Kaltsonoudis E., Pelechas E., Voulgari P.V., Drosos A.A. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin. Arthritis Rheum. 2019;48:597–602. doi: 10.1016/j.semarthrit.2018.06.003. - DOI - PubMed
    1. Summary of Product Characteristics. [(accessed on 19 March 2019)]; Available online: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-....

LinkOut - more resources